Cholesterol 1,2,3 skin test
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer & Specialty Pharmaceuticals is on short list of potential U.S. marketing partners for International Medical Innovations' Cholesterol 1,2,3 test. McNeil will market the three-minute, non-invasive cholesterol skin test in Canada; however, Toronto-based IMI says it is considering U.S. distribution deals with several other firms. Cholesterol 1,2,3 received FDA 510(k) clearance on June 24; it is indicated for use with standard blood testing for patients suspected of having severe coronary artery disease. Home version of the test is under development, IMI says...
You may also be interested in...
McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.